I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend
AbbVie is entering a new chapter of growth, fueled by its blockbuster immunology drugs and expanding neuroscience business. Investor Kevin Simpson shares why he's optimistic.
Summary from the CNBC news feed. Copyright belongs to CNBC.
Headlines and summaries come from publishers’ public news feeds and are shown with attribution and a link to the original. Investz does not write or endorse them and they are not investment advice. Disclosures.